Company will host an investor conference call today at 11:00 AM ET

LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update.

The Company will hold a conference call today at 11AM Eastern (U.S.) time. To participate in the live conference call, please dial 1-877-407-2988 five minutes prior to the scheduled conference call time and ask for the, “INmune Bio Conference Call.” International callers should dial 1-201-389-0923.  Participants can also use this link for instant telephone access to the event.

2019 and Recent Corporate Highlights on the DN-TNF Platform and NK Priming Platform:

  • Closed an initial public offering (“IPO”) and commenced trading on The Nasdaq Capital Market.
  • Added two new independent members to the board of directors; Ed Baracchini former chief business officer of Xencor, Inc. who has negotiated many transactions with pharmaceutical and biotechnology companies and; Marcia Allen, a fortune 500 executive with vast accounting and finance experience.

DN-TNF Platform Highlights:

  • Successfully reported Phase I clinical data that INB03™ demonstrates safety and efficacy in cancer patients and has announced that the Phase II program will target trastuzumab resistance in women with HER2+ breast cancer using INB03™ as part of combination therapy.
  • Awarded a $1,000,000 grant from The Alzheimer’s Association allowing INMB to initiate a Phase 1 clinical trial using XPro1595 to treat patients with Alzheimer’s Disease.
  • Awarded a $500,000 grant from The ALS Association to complete IND enabling pre-clinical studies with XPro1595 as a therapy for ALS.
  • Initiated a program in NASH with LIVNate™ the third drug development program from the DN-TNF platform, joining DN-TNF platform drug candidates INB03™ and XPro1595.
  • XPro1595 had 9 articles published in peer review journals by academic collaborators and INB03 was one of 85 abstracts (out of 885) to be given as an oral presentation at SITC2019.
  • United States Patent and Trademark Office (USPTO) has issued Patent No. 15/776,061 on January 28, 2020, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR”, which covers INmune’s INB03™ Program utilizing dominant negative TNF (DN-TNF) technology for treating cancer.

NK Priming Platform Highlights:

  • Announced publication of data on INKmune™ in Peer-Reviewed Journal PLOS ONE. INKmune™ is a novel NK cell priming platform that signals the patient’s own NK cells to target residual disease of cancer.
  • Finalized and validated manufacturing and distributions processes for INKmune™ to support up-coming clinical trials.

Professor Lowdell, CSO INmune Bio and Professor of Cell Therapy at UCL, London, and creator of the INKmune™ product said, “2019 has been a landmark year for this product and is the culmination of 20 years’ of bench-to-bedside research. We have published the molecular basis of the mechanism of action in a peer-reviewed journal, developed scaled manufacture adequate for full commercial delivery and validated an efficient and easily delivered cold supply chain for the drug. I am extremely excited about our delivery of patients into two phase I trials this year in high risk MDS cancer and ovarian cancer, two very different clinical applications.”

“2019 and year to date, has been a period of substantial progress,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We completed our first-in-man study of our DN-TNF platform in cancer and have expanded that franchise to include Alzheimer’s Disease and NASH. Additionally, we just announced pre-clinical proof-of-concept studies in ALS.   Both our NK cell priming platform and DN-TNF platform continue to generate data in the laboratory and the clinic to allow us to expand the depth and breadth of our pipeline.”  

Upcoming Milestones:

  • Report results of Phase 1 XPro1595 in Alzheimer’s Disease, expected to complete 2H 2020.
  • Enroll first patient in Phase II INB03™ program, targeting trastuzumab resistant HER2+ breast cancer using INB03™ as part of combination therapy, expected mid-2020.
  • Enroll first patient in Phase II LIVNate™ for NASH, expected mid-2020.
  • Enroll first patient in Phase I INKmune™ in High Risk MDS cancer, expected 2H 2020.
  • Enroll first patient in Phase I INKmune™ in Ovarian cancer, expected 2H 2020.

Financial Results for the Fourth Quarter Ended December 31, 2019:

Net loss attributable to common stockholders for the fourth quarter ended December 31, 2019 was $2.3 million, compared to $1.9 million for the quarter ended December 31, 2018.

Research and development expense totaled approximately $0.9 million for the fourth quarter ended December 31, 2019, compared with approximately $1.0 million for the quarter ended December 31, 2018. The decrease in research and development expense was due to the Company recording $0.3 million of contra research and development expense as a result of the receipt of a grant from the Alzheimer’s Association.  Excluding the grant, research and development expense increased during the three months ended December 31, 2019 as a result of the further advancement of our drug platforms.

General and administrative expense was approximately $1.5 million in the quarter ended December 31, 2019, compared to approximately $0.9 million in the quarter ended December 31, 2018.  The $0.6 million increase in general and administrative expense is largely due to the costs associated with being a public company and due to higher compensation cost (including higher stock-based compensation).

At December 31, 2019, the Company had cash and cash equivalents of approximately $7.0 million with no debt.  During the quarter ending December 31, 2019, the Company received $0.4 million of cash proceeds from Australia and $0.4 million of cash proceeds from the United Kingdom pursuant to research and development tax credits.

As of March 10, 2020, the Company had 10.7 million common shares outstanding.

About INmune Bio, Inc.

INmune Bio, Inc.  is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Innate Immune Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Information about Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™ and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact: 
David Moss, CFO (858) 964-3720
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact: 
James Carbonara (646) 755-7412
This email address is being protected from spambots. You need JavaScript enabled to view it.

 
CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
 December 31,
2019
  December 31,
2018
 
      
ASSETS       
CURRENT ASSETS       
Cash$6,995,525  $186,204 
Research and development tax credit receivable 568,139   592,215 
Other tax receivable 77,225   37,382 
Joint development cost receivable -   17,989 
Prepaid expenses 97,623   15,552 
Prepaid expenses – related party 26,266   - 
        
TOTAL CURRENT ASSETS 7,764,778   849,342 
        
Operating lease – right of use asset – related party 191,543   - 
Acquired in-process research and development intangible assets 16,514,000   16,514,000 
        
TOTAL ASSETS$24,470,321  $17,363,342 
        
LIABILITIES AND STOCKHOLDERS’ EQUITY       
        
CURRENT LIABILITIES       
Accounts payable and accrued liabilities$401,989  $553,221 
Accounts payable and accrued liabilities – related parties 290,102   270,545 
Operating lease, current liability – related party 8,288   - 
TOTAL CURRENT LIABILITIES 700,379   823,766 
        
Long-term operating lease liability – related party 160,164   - 
TOTAL LIABILITIES 860,543   823,766 
        
COMMITMENTS AND CONTINGENCIES       
        
STOCKHOLDERS’ EQUITY       
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding -   - 
Common stock, $0.001 par value, 200,000,000 shares authorized, 10,770,948 and
 8,719,441 shares issued and outstanding, respectively
 10,771   8,719 
Additional paid-in capital 44,833,703   25,446,196 
Common stock issuable 50,000   4,676,000 
Accumulated other comprehensive income (loss) (8,515)  6,529 
Accumulated deficit (21,276,181)  (13,597,868)
TOTAL STOCKHOLDERS' EQUITY 23,609,778   16,539,576 
        
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$24,470,321  $17,363,342 
        


 
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018
(Unaudited)
 
 2019  2018 
      
REVENUE$-  $- 
        
OPERATING EXPENSES       
General and administrative 6,016,056   9,085,100 
Research and development 3,281,945   3,354,923 
Gain on waiver of common stock issuable (1,542,000)  - 
Total operating expenses 7,756,001   12,440,023 
        
LOSS FROM OPERATIONS (7,756,001)  (12,440,023)
        
OTHER INCOME       
Interest income 77,688   - 
Total other income 77,688   - 
        
NET LOSS$(7,678,313) $(12,440,023)
        
Net loss per common share – basic and diluted$(0.75) $(1.43)
        
Weighted average number of common shares outstanding – basic and diluted 10,272,641   8,676,701 
        


 
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018
(Unaudited)
 
 2019  2018 
CASH FLOWS FROM OPERATING ACTIVITIES:     
Net loss$(7,678,313) $(12,440,023)
Adjustments to reconcile net loss to net cash used in operating activities:       
Stock-based compensation 4,096,538   10,001,359 
Gain on waiver of common stock issuable (1,542,000)  - 
Changes in operating assets and liabilities:       
Research and development tax credit receivable 24,076   (485,349)
Other tax receivable (39,843)  74,236 
Joint development cost receivable 17,989   91,135 
Prepaid expenses (82,071)  27,095 
Prepaid expenses – related party (26,266)  158,504 
Accounts payable and accrued liabilities (151,232)  426,964 
Accounts payable and accrued liabilities – related parties 19,557   87,085 
Operating lease liability – related party (23,091)  - 
Net cash used in operating activities (5,384,656)  (2,058,994)
        
CASH FLOWS FROM FINANCING ACTIVITIES:       
Net proceeds from sale of common stock 12,209,021   900,000 
Net cash provided by financing activities 12,209,021   900,000 
        
Impact on cash from foreign currency translation (15,044)  (25,513)
        
NET INCREASE (DECREASE) IN CASH 6,809,321   (1,184,507)
        
CASH AT BEGINNING OF YEAR 186,204   1,370,711 
        
CASH AT END OF YEAR$6,995,525  $186,204 
        
Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST